Indications |
Parenteral Squamous cell or testicular tumours Adult: 15,000 IU 3 times a wk or 30,000 IU twice a wk IM/IV, repeated at usual intervals of 3-4 wk up to a total cumulative dose of 500,000 IU. Elderly: Dose reduction is necessary. Renal impairment: Dose reduction is necessary. Intramuscular Lymphoma Adult: 15,000 IU once or twice a wk, up to a total cumulative dose of 225,000 IU. Elderly: Dose reduction is necessary. Renal impairment: Dose reduction is necessary. Injection Malignant effusions Adult: 60,000 IU in 100 ml of 0.9% sodium chloride instilled into the affected serous cavity, may be repeated up to a total cumulative dose of 500,000 IU. Elderly: Dose reduction is necessary. Renal impairment: Dose reduction is necessary. Incompatibility: Incompatible with solutions of essential amino acids, riboflavin, dexamethasone or furosemide. |
Contraindications |
Hypersensitivity. Severe pulmonary disease; pregnancy and lactation. |
Warnings / Precautions |
Pulmonary infection, preexisting pulmonary function impairment, renal impairment. Patients who received radiotherapy, particularly to the thorax. Regular chest x-rays should be done. Elderly. Discontinue treatment if chest x-rays show infiltrates or breathlessness occurs. |
Adverse Reactions |
Fever, thrombophloebitis (inj). Acute anaphylactoid reactions, hyperpyrexia. Rash, erythema, pruritus, vesiculation, hyperkeratosis, nail changes, alopecia, hyperpigmentation, striae, stomatitis. Potentially Fatal: Pulmonary toxicity, interstitial pneumonitis, fibrosis, cardiorespiratory collapse in patients with lymphoma. |
Drug Interactions |
Lomustine increases severity of leukopenia. Elimination decreased by cisplatin. Decreases plasma levels of digoxin and phenytoin. Potentially Fatal: Enhanced pulmonary toxicity in patients given with oxygen. See Below for More bleomycin Drug Interactions |
Mechanism of Actions |
Bleomycin causes breakage of single- and double- stranded DNA by binding to DNA and inhibiting DNA synthesis. To a lesser extent, it also inhibits RNA and protein synthesis. It causes very little bone marrow suppression. Absorption: Poorly absorbed from the GI tract (oral). Distribution: Crosses the placenta. Metabolism: Enzymatic degradation in plasma, liver and other organs. Excretion: Urine (as active drug). Elimination half-life: Initial: 0.5 hr (IV bolus), 1.3 hr (infusion); terminal: 4 hr (IV bolus), 9 hr (infusion). |
Storage Conditions |
Injection: Refrigerate at 2-8°C. Intramuscular: Refrigerate at 2-8°C. Parenteral: Refrigerate at 2-8°C. |
ATC Classification |
L01DC01 - bleomycin ; Belongs to the class of other cytotoxic antibiotics. Used in the treatment of cancer. |
Storage |
Injection: Refrigerate at 2-8°C. Intramuscular: Refrigerate at 2-8°C. Parenteral: Refrigerate at 2-8°C. |
Available As |
|
Bleomycin
Post Review about Bleomycin Click here to cancel reply.
Bleomycin Containing Brands
Bleomycin is used in following diseases
Drug - Drug Interactions of Bleomycin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.